Intraperitoneal injection of adenovirus-mediated NK4 gene suppresses peritoneal dissemination of pancreatic cancer cell line AsPC-1 in nude mice

Cancer Gene Therapy

Volumn 9, Issue 10, 2002, Pages 799-806

  Saimura, Michiyo ^a   Nagai, Eishi ^a   Mizumoto, Kazuhiro ^a   Maehara, Naoki ^a   Okino, Hidenobu ^a   Katano, Mitsuo ^a   Matsumoto, Kunio ^b   Nakamura, Toshikazu ^b   Narumi, Kou ^c   Nukiwa, Toshihiro ^c   Tanaka, Masao ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c TOHOKU UNIVERSITY   (Japan)

Author keywords

Angiogenesis inhibitor; Gene therapy; HGF antagonist; NK4; Pancreatic cancer; Peritoneal dissemination; Recombinant adenovirus

Indexed keywords

ANGIOGENESIS INHIBITOR; PROTEIN; PROTEIN NK4; SCATTER FACTOR; UNCLASSIFIED DRUG;

ADENOVIRUS; AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER SURVIVAL; CANCER THERAPY; CONTROLLED STUDY; FEMALE; GENE; GENE THERAPY; GENE TRANSFER; GENETIC TRANSDUCTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; KRINGLE DOMAIN; LIVER METASTASIS; MESENTERY TUMOR; METASTASIS INHIBITION; MICROVASCULATURE; MOUSE; NK4 GENE; NONHUMAN; NUDE MOUSE; PANCREAS CANCER; PERITONEUM LAVAGE; PERITONEUM METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN CANCER; TISSUE DISTRIBUTION; TUMOR VASCULARIZATION; VIRUS RECOMBINANT;

ADENOCARCINOMA; ADENOVIRUSES, HUMAN; ANIMALS; BETA-GALACTOSIDASE; CELL DIVISION; FEMALE; GENE THERAPY; GENETIC VECTORS; HEPATOCYTE GROWTH FACTOR; HUMANS; IMMUNOENZYME TECHNIQUES; INJECTIONS, INTRAPERITONEAL; LAC OPERON; LIVER; MESENTERY; MICE; MICE, INBRED BALB C; MICE, NUDE; MITOGENS; NEOVASCULARIZATION, PATHOLOGIC; PANCREATIC NEOPLASMS; PERITONEAL NEOPLASMS; SPLEEN; TRANSFECTION; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ADENOVIRIDAE; ANIMALIA; MUS MUSCULUS;

EID: 0036789558     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700504     Document Type: Article

References (39)

1. Gunzburg WH, Salmons B. Novel clinical strategies for the treatment of pancreatic carcinoma. Trends Mol Med. 2001; 7:30-37. (Review).
2. Niederhuber JE, Brennan MF, Menck HR. The National Cancer Data Base report on pancreatic cancer. Cancer. 1995;76:1671-1677.
3. Warshaw AL, Fernandez-del Castillo C. Pancreatic carcinoma. N Engl J Med. 1992;326:455-465.
4. Henne-Bruns D, Vogel I, Luttges J, Klöppel G, Kremer B. Ductal adenocarcinoma of the pancreas head: survival after regional versus extended lymphadenectomy. Hepatogastroenterology. 1998;45:855-866.
5. Vogel I, Kruger U, Marxsen J, et al. Disseminated tumor cells in pancreatic cancer patients detected by immunocytology: a new prognostic factor. Clin Cancer Res. 1999;5:593-599.
6. Neoptolemos JP, Dunn JA, Stocken DD, et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet. 2002;358:1576-1585.
7. Schmiegel W, Schmielau J, Henne-Bruns D, et al. Cytokine-mediated enhancement of epidermal growth factor receptor expression provides an immunological approach to the therapy of pancreatic cancer. Proc Natl Acad Sci USA. 1997; 94:12622-12626.
8. Simeone DM, Cascarelli A, Logsdon CD. Adenoviral-mediated gene transfer of a constitutively active retinoblastoma gene inhibits human pancreatic tumor cell proliferation. Surgery. 1997; 122:428-433; discussion 433-434.
9. Nakamura T, Nawa K, Ichihara A. Partial purification and characterization of hepatocyte growth factor from serum of hepatectomized rats. Biochem Biophys Res Commun. 1984; 122:1450-1459.
10. Nakamura T, Nishizawa T, Hagiya M, et al. Molecular cloning and expression of human hepatocyte growth factor. Nature. 1989;342:440-443.
11. Matsumoto K, Nakamura T. Hepatocyte growth factor (HGF) as a tissue organizer for organogenesis and regeneration. Biochem Biophys Res Commun. 1997;239:639-644.
12. Birchmeier C, Gherardi E. Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase. Trends Cell Biol. 1998;8:404-410.
13. Zamegar R, Michalopoulos GK. The many faces of hepatocyte growth factor: from hepatopoiesis to hematopoiesis. J Cell Biol. 1995;129:1177-1180.
14. Nakamura T, Matsumoto K, Kiritoshi A, Tano Y. Induction of hepatocyte growth factor in fibroblasts by tumor-derived factors affects invasive growth of tumor cells: in vitro analysis of tumor-stromal interactions. Cancer Res. 1997;57:3305-3313.
15. Seslar SP, Nakamura T, Byers SW. Regulation of fibroblast hepatocyte growth factor/scatter factor expression by human breast carcinoma cell lines and peptide growth factors. Cancer Res. 1993;53:1233-1238.
16. Di Renzo MF, Poulsom R, Olivero M, Comoglio PM, Lemoine NR. Expression of the Met/hepatocyte growth factor receptor in human pancreatic cancer. Cancer Res. 1995;55:1129-1138.
17. Maehara N, Matsumoto K, Kuba K, Mizumoto K, Tanaka M, Nakamura T. NK4, a four-kringle antagonist of HGF, inhibits spreading and invasion of human pancreatic cancer cells. Br J Cancer. 2001;84:864-873.
18. Date K, Matsumoto K, Kuba K, Shimura H, Tanaka M, Nakamura T. Inhibition of tumor growth and invasion by a four-kringle antagonist (HGF/NK4) for hepatocyte growth factor. Oncogene. 1998;17:3045-3054.
19. Date K, Matsumoto K, Shimura H, Tanaka M, Nakamura T. HGF/NK4 is a specific antagonist for pleiotrophic actions of hepatocyte growth factor. FEBS Lett. 1997;420:1-6.
20. Matsumoto K, Kataoka H, Date K, Nakamura T. Cooperative interaction between alpha-and beta-chains of hepatocyte growth factor on c-Met receptor confers ligand-induced receptor tyrosine phosphorylation and multiple biological responses. J Biol Chem. 1998;273:22913-22920.
21. Kuba K, Matsumoto K, Date K, Shimura H, Tanaka M, Nakamura T. HGF/NK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice. Cancer Res. 2000;60: 6737-6743.
22. Tomioka D, Maehara N, Kuba K, et al. Inhibition of growth, invasion, and metastasis of human pancreatic carcinoma cells by NK4 in an orthotopic mouse model. Cancer Res. 2001;61: 7518-7524.
23. Maemondo M, Narumi K, Saijo Y, et al. Targeting angiogenesis and HGF function using an adenoviral vector expressing the HGF antagonist NK4 for cancer therapy. Mol Ther. 2002;5: 177-185.
24. McGrory WJ, Bautista DS, Graham FL. A simple technique for the rescue of early region I mutations into infectious human adenovirus type 5. Virology. 1988;163:614-617.
25. Korst RJ, Bewig B, Crystal RG. In vitro and in vivo transfer and expression of human surfactant SP-A- and SP-B-associated protein cDNAs mediated by replication-deficient, recombinant adenoviral vectors. Hum Gene Ther. 1995;6:277-287.
26. Yashiro M, Chung YS, Inoue T, et al. Hepatocyte growth factor (HGF) produced by peritoneal fibroblasts may affect mesothelial cell morphology and promote peritoneal dissemination. Int J Cancer. 1996;67:289-293.
27. Vande Woude GF, Jeffers M, Cortner J, Alvord G, Tsaffaty I, Resau J. Met-HGF/SF: tumorigenesis, invasion and metastasis. Ciba Found Symp. 1997;212:119-130; discussion 130-132, 148-154.
28. Jiang W, Hiscox S, Matsumoto K, Nakamura T. Hepatocyte growth factor/scatter factor, its molecular, cellular and clinical implications in cancer. Crit Rev Oncol Hematol. 1999;29:209- 248.
29. Furukawa T, Duguid WP, Kobari M, Matsuno S, Tsao MS. Hepatocyte growth factor and Met receptor expression in human pancreatic carcinogenesis. Am J Pathol. 1995;147:889-895.
30. Ebert M, Yokoyama M, Friess H, Buchler MW, Korc M. Coexpression of the c-met proto-oncogene and hepatocyte growth factor in human pancreatic cancer. Cancer Res. 1994;54:5775-5778.
31. Paciucci R, Vila MR, Adell T, et al. Activation of the urokinase plasminogen activator/urokinase plasminogen activator receptor system and redistribution of E-cadherin are associated with hepatocyte growth factor-induced motility of pancreas tumor cells overexpressing Met. Am J Pathol. 1998;153:201-212.
32. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995;1:27-31.
33. Ikeda N, Adachi M, Taki T, et al. Prognostic significance of angiogenesis in human pancreatic cancer. Br J Cancer. 1999; 79:1553-1563.
34. Kawarada Y, Ishikura H, Kishimoto T, et al. Inhibitory effects of the antiangiogenic agent TNP-470 on establishment and growth of hematogenous metastasis of human pancreatic carcinoma in SCID beige mice in vivo. Pancreas. 1997;15:251-257.
35. Bruns CJ, Solorzano CC, Harbison MT, et al. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res. 2000;60: 2926-2935.
36. Schwarte-Waldhoff I, Volpert OV, Bouck NP, et al. Smad4/DPC4-mediated tumor suppression through suppression of angiogenesis. Proc Natl Acad Sci USA. 2000;97:9624-9629.
37. Kuba K, Matsumoto K, Ohnishi K, Shiratsuchi T, Tanaka M, Nakamura T. Kringle 1-4 of hepatocyte growth factor inhibits proliferation and migration of human microvascular endothelial cells. Biochem Biophys Res Commun. 2000;279:846-852.
38. Kozarsky KF, Wilson JM. Gene therapy: adenovirus vectors. Curr Opin Genet Dev. 1993;3:499-503.
39. Grace MJ, Xie L, Musco ML, et al. The use of laser scanning cytometry to assess depth of penetration of adenovirus p53 gene therapy in human xenograft biopsies. Am J Pathol. 1999;155:1869-1878.